Evidence map›Paper›PMID 28733702›Full record

ArticleInvestigational new drugs2017

Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Miodrag Dragoj, Jasna Bankovic, Evangelia Sereti, Sofija Jovanovic Stojanov, Konstantinos Dimas, Milica Pesic, Tijana Stankovic

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.Journal of experimental & clinical cancer research : CR · 2019
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Miodrag DragojDepartment of Neurobiology, University of Belgrade, Institute for Biological Research "Sinisa Stankovic", Bulevar Despota Stefana 142, Belgrade, 11060, Serbia.
Jasna BankovicDepartment of Neurobiology, University of Belgrade, Institute for Biological Research "Sinisa Stankovic", Bulevar Despota Stefana 142, Belgrade, 11060, Serbia.
Evangelia SeretiDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41110, Larissa, Greece.
Sofija Jovanovic StojanovDepartment of Neurobiology, University of Belgrade, Institute for Biological Research "Sinisa Stankovic", Bulevar Despota Stefana 142, Belgrade, 11060, Serbia.
Konstantinos DimasDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41110, Larissa, Greece.
Milica PesicDepartment of Neurobiology, University of Belgrade, Institute for Biological Research "Sinisa Stankovic", Bulevar Despota Stefana 142, Belgrade, 11060, Serbia.
Tijana StankovicDepartment of Neurobiology, University of Belgrade, Institute for Biological Research "Sinisa Stankovic", Bulevar Despota Stefana 142, Belgrade, 11060, Serbia. tijana.andjelkovic@ibiss.bg.ac.rs.ORCID http://orcid.org/0000-0001-5623-0612
University of Belgrade · RSUniversity of Thessaly · GR

Funding

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja III41031
6 · The paper itself

Abstract

Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. At the time of diagnosis, a large percentage of NSCLC patients have already developed metastasis, responsible for extremely high mortality rates. CXCR4 receptor and focal adhesion kinase (FAK) are known to regulate such invasive cancer behavior. Their expression is downregulated by p53 and PTEN tumor suppressors which are commonly co-inactivated in NSCLC patients and contribute to metastasis. Therefore, targeting CXCR4 or FAK seems to be a promising strategy in suppressing metastatic spread of p53/PTEN deficient NSCLCs. In this study, we first examined the invasive characteristics of NSCLC cells with suppressed p53 and PTEN activity using wound healing, gelatin degradation and invasion assays. Further, changes in the expression of CXCR4 and FAK were evaluated by RT-qPCR and Western Blot analysis. Finally, we tested the ability of CXCR4 and FAK inhibitors (WZ811 and PF-573228, respectively) to suppress the migratory and invasive potential of p53/PTEN deficient NSCLC cells, in vitro and in vivo using metastatic models of human NSCLC. Our results showed that cells with mutually inactive p53 and PTEN have significantly increased invasive potential associated with hyperactivation of CXCR4 and FAK signaling pathways. Treatments with WZ811 and PF-573228 inhibitors significantly reduced migratory and invasive capacity in vitro and showed a trend of improved survival in vivo. Accordingly, we demonstrated that p53/PTEN deficient NSCLCs have extremely invasive phenotype and provided a rationale for the use of CXCR4 or FAK inhibitors for the suppression of NSCLC dissemination.

Indexed as

AnimalsApoptosisCarcinoma, Non-Small-Cell LungCell ProliferationEnzyme InhibitorsFocal Adhesion Kinase 1Gene Expression Regulation, NeoplasticHumansLung NeoplasmsMiceMice, Inbred NODMice, SCIDNeoplasm InvasivenessPTEN PhosphohydrolaseReceptors, CXCR4Tumor Cells, CulturedCXCR4 protein, humanEnzyme InhibitorsFocal Adhesion Kinase 1PTEN PhosphohydrolasePTEN protein, humanPTK2 protein, humanReceptors, CXCR4TP53 protein, humanTumor Suppressor Protein p53CXCR4FAKInvasionNon-small cell lung carcinomap53PTEN

Identifiers

PMID28733702
OpenAlexW2737458349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.